Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

60.0%

-26.6% vs industry average

Late-Stage Pipeline

28%

7 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

14 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

15(62.5%)

Phase 3

7(29.2%)

Phase 2

2(8.3%)

24Total

Phase 1(15)

Phase 3(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT07491445Phase 3Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT06881784Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Role: lead

NCT07621718Phase 3Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Role: lead

NCT07252232Phase 3Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT06128551Phase 1Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Role: lead

NCT06445062Phase 1Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Role: lead

NCT07349537Phase 1Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Role: lead

NCT07805954Phase 3Recruiting

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Role: lead

NCT07573215Unknown

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT07793253Phase 2Not Yet Recruiting

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Role: collaborator

NCT07777822Phase 3Recruiting

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Role: lead

NCT07756281Phase 1Not Yet Recruiting

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Role: collaborator

NCT07397338Phase 1Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Role: lead

NCT06162221Phase 1Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Role: lead

NCT06040541Phase 1Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Role: lead

NCT06625320Phase 3Active Not Recruiting

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

NCT05379985Phase 1Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Role: lead

NCT05462717Phase 1Active Not Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Role: lead

NCT06922591Phase 1Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Role: collaborator

NCT05557292Phase 1Terminated

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Role: collaborator